Egyptian Board Clinical Oncology common mistakes
Egyptian Board Clinical Oncology · Understand the traps and how to avoid them.
When asked to select the best next step for a patient with newly diagnosed metastatic non-small cell lung cancer, the candidate chooses a targeted agent based on histology alone (e.g., "adenocarcinoma → pemetrexed/platinum") without first confirming actionable biomarker status (EGFR, ALK, ROS1, BRAF, MET, RET, KRAS G12C, PD-L1) and without checking whether the question stem already supplies a molecular result that overrides chemotherapy.
Training emphasizes regimen memorization by histology; candidates skim the stem for the diagnosis and jump to a familiar regimen, missing the single line stating "EGFR exon 19 deletion" or "PD-L1 TPS 80%." Under time pressure, biomarker-driven sequencing feels slower than pattern-matching.
What to do instead
Adopt a fixed reading order for every thoracic systemic-therapy item: (1) histology, (2) stage/line of therapy, (3) any molecular or PD-L1 data in the stem, (4) performance status. Write the biomarker result on scratch paper before looking at options. If no biomarker is given and the stem asks for "best initial therapy," the correct answer usually includes testing first, not empiric chemotherapy.
In breast cancer items, the candidate applies the same endocrine strategy regardless of menopausal status and prior therapy-for example, choosing an aromatase inhibitor alone in a premenopausal woman with hormone receptor-positive metastatic disease, or continuing the same endocrine agent after progression instead of switching class (e.g., to fulvestrant) or adding a CDK4/6 inhibitor or targeted agent per the line of therapy.
Memorized lists of "tamoxifen vs AI" blur together, and candidates do not anchor the choice to ovarian function, line of therapy, and prior endocrine exposure. The distinction between adjuvant and metastatic intent is also frequently lost.
What to do instead
Build a two-axis grid on scratch paper: menopausal/ovarian status (pre- vs postmenopausal, or on ovarian suppression) × setting (adjuvant vs first-line metastatic vs after progression). For each cell, name one endocrine option and one targeted add-on. In premenopausal metastatic disease, remember ovarian suppression plus endocrine therapy, and reserve AI monotherapy for postmenopausal or suppressed patients.
On radiation oncology physics and technique questions, the candidate answers from clinical intuition ("more dose is better," "IMRT is always superior") rather than applying the underlying principle-e.g., confusing dose vs dose rate, mixing up the definitions of GTV/CTV/PTV, or failing to recognize that a question about spinal cord tolerance or re-irradiation is testing cumulative dose constraints and fractionation (BED/EQD2) rather than tumor control.
Physics and radiobiology are perceived as low-yield and are often skipped in favor of drug regimens. Candidates also conflate volumetric definitions and do not routinely convert between fractionation schemes, so items requiring BED or EQD2 comparison collapse into guessing.
What to do instead
Maintain a one-page physics sheet: target volume definitions (GTV, CTV, ITV, PTV, OAR), the BED formula (nd[1+d/(α/β)]) with α/β = 10 for tumor and 3 for late tissue, and a short list of key OAR constraints (cord, brainstem, optic chiasm, lung V20, mean heart dose). Practice one BED calculation daily until it is automatic, and for any re-irradiation stem, explicitly sum prior and planned doses before choosing.
In gastrointestinal oncology items, the candidate selects a systemic regimen without first establishing the treatment intent and the resectability status-e.g., giving adjuvant chemotherapy for a colon cancer that is actually stage II with high-risk features requiring a different discussion, or treating a borderline-resectable pancreatic or gastric cancer as if it were metastatic, skipping the neoadjuvant/perioperative sequence that the stem is testing.
GI questions embed the decision in a long clinical vignette with imaging and pathology details; candidates latch onto the histology and miss the resectability descriptor or the line of therapy. Perioperative vs adjuvant vs palliative pathways for esophagus, stomach, pancreas, and rectum are easily confused.
What to do instead
For every GI item, write three words before answering: site, stage/resectability, intent (curative vs palliative). Then match to the pathway: rectal cancer → neoadjuvant chemoradiation sequencing; gastric/esophageal → perioperative chemotherapy; pancreatic → neoadjuvant in borderline-resectable; colon → adjuvant by stage and risk features. Reject any option that violates the intent you wrote down.
In genitourinary oncology, the candidate treats metastatic prostate cancer uniformly-failing to distinguish hormone-sensitive from castration-resistant disease, and not integrating the appropriate intensification (e.g., docetaxel or an androgen receptor pathway inhibitor plus ADT in high-volume hormone-sensitive disease) or the sequence of agents after progression on abiraterone/enzalutamide. Similar errors occur in renal cell carcinoma when the candidate ignores risk group and histology before choosing first-line immunotherapy-based combinations.
GU systemic therapy has changed rapidly, and older frameworks (ADT alone, single-agent TKI) persist in memory. Candidates also do not routinely classify by disease volume and risk category, which are the discriminators the item is built around.
What to do instead
Create a GU decision map: prostate → hormone-sensitive (volume/risk → ADT alone vs ADT + intensification) vs castration-resistant (prior ARPI? prior docetaxel? → next-line choice); kidney → clear cell vs non-clear cell and IMDC risk group → IO/IO+TKI vs TKI; bladder → neoadjuvant cisplatin-based vs palliative by cisplatin eligibility. State the classification aloud before reviewing options.
In gynecologic oncology, the candidate chooses therapy by diagnosis alone and ignores the molecular and histologic subtype that drives the answer-e.g., treating all endometrial cancers the same regardless of mismatch repair status or p53 status, or managing ovarian cancer without distinguishing upfront debulking from neoadjuvant chemotherapy and without incorporating BRCA/HRD status into maintenance decisions.
Ovarian and endometrial cancer questions increasingly test biomarker-defined pathways, but candidates still rely on older "carboplatin/paclitaxel" reflexes. The distinction between primary debulking and interval debulking, and between first-line and maintenance settings, is frequently collapsed.
What to do instead
For each gynecologic item, identify: (1) histologic subtype, (2) molecular markers given in the stem (BRCA, HRD, MMR/MSI, p53), (3) surgical setting (upfront vs interval), (4) line and maintenance phase. Then map: ovarian → platinum-based backbone plus maintenance by BRCA/HRD; endometrial → chemotherapy ± immunotherapy by MMR status; cervical → chemoradiation with cisplatin and brachytherapy for locally advanced disease.
In hematologic malignancy items, the candidate conflates induction, consolidation, and maintenance phases, or applies a regimen across diseases-e.g., using a lymphoma regimen for acute leukemia, or answering a transplant question without first determining eligibility (age, performance status, comorbidity, disease status) and donor/stem cell source. Transplant-related items are answered as if HSCT were a single procedure rather than autologous vs allogeneic with distinct indications.
Hematology has the densest regimen nomenclature and the most layered treatment phases; candidates memorize drug names without the phase structure. Transplant indications (myeloma, lymphoma, AML, aplastic anemia) are learned as a list rather than as eligibility criteria.
What to do instead
Organize hematology by disease → phase (induction/consolidation/maintenance) → transplant eligibility. For any HSCT item, answer three questions first: autologous or allogeneic, what is the indication, and is the patient fit? Then evaluate options. Memorize a short list of transplant indications and the standard eligibility thresholds used in the stem (age, organ function, performance status).
In head and neck and CNS tumor items, the candidate ignores functional anatomy and organ-preservation principles-e.g., recommending surgery where definitive chemoradiation is standard for locally advanced larynx/oropharynx disease, or failing to link CNS tumor molecular markers (IDH, 1p/19q codeletion, MGMT promoter methylation) to the diagnosis and treatment plan.
Candidates treat head and neck questions as pure surgical or pure radiation questions and miss the multidisciplinary trade-off. CNS tumor classification has shifted to molecularly defined entities, but older histology-only frameworks persist in memory.
What to do instead
For head and neck, state the subsite, stage, and whether the goal is organ preservation; then apply the standard of surgery vs definitive radiotherapy ± systemic therapy. For CNS, write the molecular profile from the stem (IDH, 1p/19q, MGMT, H3K27M) and map it to the integrated diagnosis before selecting treatment. Practice a short list of molecularly defined CNS entities and their standard management.
In pediatric and adolescent oncology, the candidate applies adult dosing, adult staging, or adult treatment paradigms to a child-e.g., using adult-type chemotherapy schedules without recognizing protocol-based risk stratification, or managing a pediatric sarcoma or leukemia without accounting for age-specific biology, late effects, and the role of clinical trials.
Pediatric oncology is a small fraction of the curriculum and is often skimmed; adult oncology habits dominate. Candidates also underestimate how much pediatric answers hinge on risk-group assignment and protocol enrollment rather than drug choice alone.
What to do instead
For pediatric items, identify the diagnosis, age, and risk group first, then recall the protocol framework (e.g., risk-adapted multiagent therapy for ALL, neoadjuvant chemotherapy for osteosarcoma, multimodality therapy for Wilms tumor). Flag late-effect considerations (fertility, cardiac, neurocognitive, secondary malignancy) whenever the stem asks about survivorship or long-term planning.
In supportive care, palliative care, and oncologic emergencies, the candidate reflexively chooses the most aggressive oncologic intervention-e.g., giving chemotherapy for malignant spinal cord compression before dexamethasone and urgent radiotherapy/surgery, or failing to recognize febrile neutropenia as an emergency requiring immediate empiric broad-spectrum antibiotics rather than awaiting culture results.
The exam rewards oncologic knowledge, so candidates default to cancer-directed therapy and overlook the time-critical, supportive-first sequence. Emergency items are often short and easy to misread as treatment-selection questions.
What to do instead
Memorize a one-page emergency algorithm: febrile neutropenia → cultures then immediate empiric antipseudomonal coverage; cord compression → dexamethasone immediately, then imaging and urgent decompression/radiotherapy; tumor lysis syndrome → hydration, allopurinol/rasburicase, electrolyte monitoring; hypercalcemia → IV fluids then bisphosphonate; SVC syndrome → assess airway and consider stenting plus radiotherapy. For any palliative item, ask what relieves suffering fastest before what treats the tumor.